People are all biologically unique and have their own individual genetic backgrounds. 23andMe aims to help its customers learn more about where they come from, as well as track their health, especially during a turbulent era for global well-being.
The Sunnyvale-based company has capped off 2020 by securing $82.5 million in fresh equity funding, as reported by TechCrunch and confirmed by Bloomberg. The investment came from participants including Sequoia Capital and NewView Capital.
With 23andMe’s at-home testing kits, customers can send a DNA sample and receive personalized information about their genetics, teaching them more about their family tree and providing them with insights about their health.
Not only do customers enjoy learning about their ancestry, but their DNA can also help contribute to medical research. Using de-identified, aggregated data, the company has begun looking into how certain genetic traits could affect an individual’s susceptibility to the COVID-19 virus. According to the company site, it’s found a person’s blood type to be one such indicator.
This Series F round for 23andMe reportedly brings the company’s total funding to more than $850 million. The new capital will be used to help the company continue to grow.
